Rafal Olszanecki (Rafał Olszanecki)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 4

Top Topics

Epidermal Growth Factor Receptor

Cardiovascular Disease

Nitric Oxide Synthase

Top Venues

Clinical and experimental pharmacology & physiology

Cardiovascular drugs and therapy

Oxidative medicine and cellular longevity

Disease markers

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Kiepura, Maciej Suski, Kamila Stachyra, Katarzyna Kuś, Klaudia Czepiel, Anna Wiśniewska, Magdalena Ulatowska-Białas, Rafal Olszanecki
The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice. Cardiovascular drugs and therapy (2023)
Viktoria Dobrocsyova, Miroslava Slamkova, Katarina Krskova, Lucia Balazova, Maciej Suski, Rafal Olszanecki, Sona Cacanyiova, Stefan Zorad
AVE0991, a Nonpeptide Angiotensin 1-7 Receptor Agonist, Improves Glucose Metabolism in the Skeletal Muscle of Obese Zucker Rats: Possible Involvement of Prooxidant/Antioxidant Mechanisms. Oxidative medicine and cellular longevity 2020 (2020)
Aneta Stachowicz, Rafal Olszanecki, Maciej Suski, Anna Wiśniewska, Katarzyna Kuś, Magdalena Białas, Jacek Jawień, Ryszard Korbut
Quantitative proteomics reveals decreased expression of major urinary proteins in the liver of apoE/eNOS-DKO mice. Clinical and experimental pharmacology & physiology 45 (7) (2018)
Agnieszka Żyłka, Agnieszka Gala-Błądzińska, Paulina Dumnicka, Piotr Ceranowicz, Marek Kuźniewski, Krzysztof Gil, Rafal Olszanecki, Beata Kuśnierz-Cabala
Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes. Disease markers 2016 (2016)